Business
Correction to Faron´s Annual Report 2019
Correction to Faron´s Annual Report 2019.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n RNS Number : 6962H\n Faron Pharmaceuticals Oy\n 26 March 2020\n \n \n \n \n Faron Pharmaceuticals Oy\n \n \n (\"Faron\" or the \"Company\")\n \n \n \n \n \n Correction to Faron´s Annual Report 2019 \n \n \n \n \n \n \n \n \n Company announcement, 26 March 2020 at 12.00 PM (EET)\n \n \n \n \n \n \n \n TURKU - FINLAND \n \n - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces the correction to the Annual Report 2019 which has been published yesterday.\n \n \n \n \n \n The correction is related to the average number of shares and EPS (loss per share). The correct average number of shares is \n 36,850,577 \n not 35,533,179 in 2019 as published earlier yesterday in the Annual Report 2019 and in the Financial statement release published on 20 March 2020. The resulting EPS is (0.36) for the full year 2019. Loss per share unaudited 7-12/2019 is (0.18) and unaudited 7-12/2018 is (0.20). \n \n \n \n \n \n The corrected versions of Faron Pharmaceuticals´ Annual Report 2019 and financial statements for the accounting period 1 January - 31 December 2019 have been published in English and its financial statements in Finnish, on the Company's website https://www.faron.com/investors/results.\n \n \n \n \n \n \n \n \n For more information please contact:\n \n \n \n \n \n Faron Pharmaceuticals Oy\n \n \n Dr Markku Jalkanen, Chief Executive Officer\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n Panmure Gordon (UK) Limited, Nomad and Broker\n \n \n Emma Earl, Freddy Crossley (Corporate Finance)\n \n \n James Stearns (Corporate Broking)\n \n \n Phone: +44 207 886 2500\n \n \n \n \n \n Sisu Partners Oy, Certified Adviser on Nasdaq First North\n \n \n Juha Karttunen, Jussi Majamaa\n \n \n Phone: +358 (0)40 555 4727\n \n \n \n \n \n Consilium Strategic Communications\n \n \n Mary-Jane Elliott, David Daley, Lindsey Neville\n \n \n Phone: +44 (0)20 3709 5700\n \n \n E-mail: \n \n \n [email protected]\n \n \n \n \n \n \n \n About Faron Pharmaceuticals Ltd \n \n \n Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pip...